Results 251 to 260 of about 19,491,478 (363)

The predictive value of fibrosis profiles for hepatitis E virus-related liver failure among hospitalized patients with acute hepatitis E: a retrospective cohort study. [PDF]

BMC Infect Dis
Dong R, Huang L, Chen L, Xue H, Shao J, Ye C, Yang Y, Xu K, Luo Z, Wang J.   +9 more
europepmc   +1 more source

Antibody to Hepatitis B e Positive Hepatitis Induced by Withdrawal of Steroid Therapy for Polymyositis: Response to Interferon-Alpha and Cyclosporin A.

, 1998
Kimio Nakanishi, Maki Ishikawa, Masahito Nakauchi, Atsushi Sakurai, Kazuaki Doi, Yoshiyasu Taniguchi   +5 more
openalex   +2 more sources

Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016

Clinical Infectious Diseases, 2018
J. Lai, G. Wong, T. Yip, Y. Tse, K. Lam, G. Lui, H. Chan, V. Wong   +7 more
semanticscholar   +1 more source

Model‐based evaluation of the interaction between ritonavir‐boosted atazanavir and rifampicin in Ugandan adults with HIV

British Journal of Clinical Pharmacology, EarlyView.
Aim Concomitant treatment of tuberculosis (TB) and human immunodeficiency virus (HIV) is complicated by drug‐drug interactions (DDI). This analysis aimed to characterize the DDI between ritonavir‐boosted atazanavir (ATV/r) and rifampicin in plasma and peripheral blood mononuclear cells (PBMC).
Allan Kengo, Juan Eduardo Resendiz‐Galvan, Letisha Najjemba, Henry Mugerwa, Amedeo De Nicolò, Antonio D'Avolio, Shakir Atoyebi, Lubbe Wiesner, Elin M. Svensson, Catriona Waitt, Paolo Denti   +10 more
wiley   +1 more source

Hepatitis E virus infection-triggered intrahepatic cholestasis: A case report. [PDF]

World J Hepatol
Drexler S, Haedge F, Weber SN, Krawczyk M, Matter MS, Geppert CI, Weber A, Stieger B, Trautwein C, Kremer AE.   +9 more
europepmc   +1 more source

The global burden of hepatitis E outbreaks: a systematic review

Liver international (Print), 2017
M. Hakim, Wenshi Wang, W. Bramer, Jiawei Geng, Fen Huang, R. A. Man, M. Peppelenbosch, Q. Pan   +7 more
semanticscholar   +1 more source

Clinical Images: Penetrating aortic ulceration as an initial presentation of Erdheim‐Chester disease

Arthritis &Rheumatology, EarlyView.
Jerome Razanamahery, Bernard Bonnotte
wiley   +1 more source

Adverse drug reactions, particularly liver disorders, drive interruptions in anti‐tuberculosis treatment: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aims Adverse drug reactions (ADRs) are a key driver of missed doses of anti‐tuberculosis (TB) therapy. We aimed to determine the relative burden of ADR‐driven missed doses, the missed dose patterns associated with ADRs, and the association between specific ADRs and missed doses.
Eleanor G. Dixon, Evita Biraua, Edvards Brencsēns, Vitālijs Pašuks, Vija Riekstina, Anete Šperberga, Marisa D. Muckian, James W. Dear, Liga Kuksa, Derek J. Sloan, Helen R. Stagg   +10 more
wiley   +1 more source

Type E hepatitis: State of the Art

, 1997
Mikhail S. Balayan
openalex   +1 more source

Recurrent fexuprazan‐induced liver injury following unintentional re‐exposure

British Journal of Clinical Pharmacology, EarlyView.
Fexuprazan, a potassium‐competitive acid blocker, is increasingly used for the treatment of gastroesophageal reflux disease in South Korea. While generally well tolerated, data regarding its hepatotoxic potential are scarce. We report a case of idiosyncratic drug‐induced liver injury in a 61‐year‐old woman following 2 months of fexuprazan therapy.
Sook Jin Seong, O Seong Kweon, Young‐Ran Yoon, Yu Kyung Kim, Yoo Na Kang, Se Young Jang   +5 more
wiley   +1 more source